Journal of Thrombosis and Thrombolysis

, Volume 44, Issue 1, pp 71–75 | Cite as

New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice

  • A. GirolamiEmail author
  • E. Cosi
  • S. Ferrari
  • A. M. Lombardi
  • B Girolami


Recently several variants of clotting factors have shown a peculiar behavior so that they appear as new defects. The factors involved are FII, FV and FIX. Prothrombin deficiency is usually associated with bleeding. Recently a few prothrombin abnormalities involving Arg396 mutations, have been demonstrated to show antithrombin resistance with the consequent appearance of a thrombophilic state and venous thromboses in young age. The same is true for an abnormal FIX (FIX Padua). The thrombotic manifestations in the latter condition are also venous. The abnormal FIX (FIX Padua) is characterized by a great increase in FIX activity whereas FIX antigen is only slightly increased. The condition is due to an Arg338Lys mutation. The increased intrinsic clotting activity of this abnormal FIX is being investigated as a useful therapeutic approach in homophile B patients. Another new clotting disorder is represented by two abnormal FV (FV East Texas and FV Amsterdam). These are characterized by a deletion of part of the B domain of FV resulting in a “short” FV. The condition is characterized by a mild bleeding tendency due to high levels of Tissue Factor pathway inhibitor. The “short” factor V is in fact resistant to the action of Tissue Factor pathway inhibitor which is sharply increased in these patients. These new clotting entities have again demonstrated that the study of patients who show a tendency to venous thrombosis or a mild bleeding condition that cannot be explained on the basis of our current concepts of blood coagulation, may represent “new” coagulation disorders. All persons interested in thrombotic or hemorrhagic disorders should be informed about these new clinical and laboratory conditions.


Clotting disorders Antithrombotic resistance Abnormal Factor V Short FV FIX abnormality 



This study was supported in part by the Associazione Emofilia ed altre coagulopatie delle Tre Venezie.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Shmerling DH, Jung E, Duckert F (1960) Eine neue familiäre Koagulopathie infolge Mangels an fibrinstabilisierendem Faktor. Helv. paediat. Acta 15:171–175Google Scholar
  2. 2.
    Hougie C, Twomey JJ (1967) Haemophilia Bm: a new type of factor-IX deficiency. Lancet 1:698–700CrossRefGoogle Scholar
  3. 3.
    Girolami A, Molaro G, Lazzarin M, Scarpa R, Brunetti A (1970) A “new” congenital haemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): study of a large kindred. Br J Haematol 19:179–192CrossRefGoogle Scholar
  4. 4.
    Girolami A, Bareggi G, Brunetti A, Sticchi A (1974) Prothrombin padua: a “new” congenital dysprothrombinemia. J Lab Clin Med 84:654–666PubMedGoogle Scholar
  5. 5.
    Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M (1979) Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 63:877–884CrossRefGoogle Scholar
  6. 6.
    Dahlbäck B, Carlsson M, and Svensson P J (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1; 90: 1004–1008.CrossRefGoogle Scholar
  7. 7.
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67CrossRefGoogle Scholar
  8. 8.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMedGoogle Scholar
  9. 9.
    Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M, Okamoto K, Matsushita T, Naoe T, Saito H, Kojima T (2012) Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 366:2390–2396CrossRefGoogle Scholar
  10. 10.
    Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, Finn JD, Spiezia L, Radu C, Arruda VR (2009) X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 361:1671–1675CrossRefGoogle Scholar
  11. 11.
    Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B (2013) Coagulation factor V (A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 123:3777–3787CrossRefGoogle Scholar
  12. 12.
    Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S (2015) A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 125:1822–1825CrossRefGoogle Scholar
  13. 13.
    Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A (1998) Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinol 9:557–569CrossRefGoogle Scholar
  14. 14.
    Lancellotti S, Basso M, De Cristofaro R (2013) Congenital prothrombin deficiency: an update. Semin Thromb Hemost 39:596–606CrossRefGoogle Scholar
  15. 15.
    Girolami A, Candeo N, Vettore S, Lombardi AM, Girolami B (2010) The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. J Thromb Thrombol 29:299–302CrossRefGoogle Scholar
  16. 16.
    Djordjevic V, Kovac M, Miljic P, Murata M, Takagi A, Pruner I, Francuski D, Kojima T, Radojkovic D (2013) A novel prothrombin mutation in two families with prominent thrombophilia – the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 11:1936–1939PubMedGoogle Scholar
  17. 17.
    Kishimoto M, Suzuki N, Murata M, Ogawa M, Kanematsu T, Takagi A, Kiyoi H, Kojima T, Matsushita T (2016) The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol 95:541–542CrossRefGoogle Scholar
  18. 18.
    Sivasundar S, Oommen AT, Prakash O, Baskaran S, Biswas R, Nair S, Mohan CG, Biswas L (2013) Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 50:182–183CrossRefGoogle Scholar
  19. 19.
    Bulato C, Radu CM, Campello E, Gavasso S, Spiezia L, Tormene D, Simioni P (2016) New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler Thromb Vasc Biol 36:1022–1029CrossRefGoogle Scholar
  20. 20.
    Henriksen RA, Dunham CK, Miller LD, Casey JT, Menke JB, Knupp CL, Usala SJ (1998) Prothrombin Greenville, Arg517⟶Gln, identified in an individual heterozygous for dysprothrombinemia. Blood 91:2026–2031PubMedGoogle Scholar
  21. 21.
    Kuang SQ, Hasham S, Phillips MD, Wolf D, Wan Y, Thiagarajan P, Milewicz DM (2001) Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas. Blood 97:1549–1554CrossRefGoogle Scholar
  22. 22.
    Broze GJ Jr, Girard TJ (2013) Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder. J Clin Invest 123:3710–3712CrossRefGoogle Scholar
  23. 23.
    Dahlbäck B (2016) Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol 38(Suppl 1):4–11CrossRefGoogle Scholar
  24. 24.
    Wood JP, Ellery PE, Maroney SA, Mast AE (2014) Biology of tissue factor pathway inhibitor. Blood 123:2934–2943CrossRefGoogle Scholar
  25. 25.
    Lozier JN. Gene therapy. Factor IX Padua: them that have, give. Blood. 2012: 29;120:4452–4453.CrossRefGoogle Scholar
  26. 26.
    Cantore A, Nair N, Della Valle P, Di Matteo M, Màtrai J, Sanvito F, Brombin C, Di Serio C, D’Angelo A, Chuah M, Naldini L, Vandendriessche T (2012) Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 120:4517–4520.CrossRefGoogle Scholar
  27. 27.
    Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, Samulski RJ (2015) Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 26:69–81.CrossRefGoogle Scholar
  28. 28.
    Koenderman JS, Bertina RM, Reitsma PH, de Visser MC (2011) Factor IX-R338L (Factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism. Thromb Res 128:603CrossRefGoogle Scholar
  29. 29.
    de Moraes Mazetto B, Orsi FL, Siqueira LH, de Mello TB, de Paula EV, Annichino-Bizzacchi JM (2010) Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels. Thromb Res 126:165CrossRefGoogle Scholar
  30. 30.
    Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B (2010) Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombol 30:172–178CrossRefGoogle Scholar
  31. 31.
    Girolami A, Cosi E, Santarossa C, Ferrari S, Luigia Randi M (2015) The story of serum prothrombin conversion accelerator, proconvertin, stable factor, cothromboplastin, prothrombin accelerator or autoprothrombin I, and their subsequent merging into factor VII. Semin Thromb Hemost 41:366–373CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • A. Girolami
    • 1
    Email author
  • E. Cosi
    • 1
  • S. Ferrari
    • 1
  • A. M. Lombardi
    • 1
  • B Girolami
    • 2
  1. 1.Department of MedicineUniversity of Padua Medical SchoolPaduaItaly
  2. 2.Division of MedicinePadua City HospitalPaduaItaly

Personalised recommendations